SESSION X: AGGRESSIVE B-CELL LYMPHOMA

Session Chairs:  Jason R. Westin, MD, MS, FACP and Jennifer Crombie, MD

Is It Time for Tailored Therapy in Frontline DLBCL? | Jason R. Westin, MD, MS, FACP | MD Anderson Cancer Center, Houston, Texas, USA

When Should Bispecific Antibodies Be Used in Aggressive B-Cell Lymphoma? | Jeremy S. Abramson, MD | Massachusetts General Hospital, Boston, Massachusetts, USA

Holding and Bridging Therapy Selection in Relapsed/Refractory Aggressive B-Cell Lymphoma | Gloria Iacoboni, MD, PhD | Vall d'Hebron University Hospital, Barcelona, Spain

Treatment Approaches for Transformed Lymphoma | Jennifer Crombie, MD | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Treatment of Rarer Subtypes of Aggressive B-Cell Lymphoma: TCRBCL, EBV-Positive DLBCL and Plasmablastic Lymphoma | Mark J. Roschewski, MD | NCI Center for Cancer Research, Bethesda, Maryland, USA

What Is the Potential of AI Remote Patient Monitoring for Lymphoma? | Jonas Paludo, MD | Mayo Clinic Rochester, Rochester, Minnesota, USA

Oral Abstract | ABCL-1492: Mosunetuzumab Plus Polatuzumab Vedotin (M-Pola) Is Superior to Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Autologous Stem Cell Transplant (ASCT)-Ineligible Patients With Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL): Primary Results of the Phase 3 SUNMO Trial | Adam J. Olszewski, MD | Brown University, Providence, Rhode Island, USA

Oral Abstract | ABCL-777: Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) | Juan Pablo Alderuccio, MD | Sylvester Comprehensive Cancer Center, Miami, Florida, USA